EUVIMEDEUVIMED entdecken
Crossref

TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signaling

Wenhao Li, Niannian Wang, Dania El Abyad, Seray Anak, Raju Kumar, Iris Ginés, Upkar Gill, Gillian Hood, James Brindley, Charles Mein, James Boot, Una Rose Wilcox und 15 weitere

Science Advances · 20.11.2026 · 12 (47)

DOI: 10.1126/sciadv.aef9541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 20.11.2026. Verfasst von Wenhao Li und 26 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Eureka Therapeutics, Medical Research Council, Academy of Medical Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a strong predictor of clinical outcomes in metabolic dysfunction–associated steatohepatitis (MASH). Fibrosis is a consequence of persistent liver cell injury and inflammation in which Toll-like receptors (TLRs) play a key initiating role. Here, we test the hypothesis that TLR5 is involved in the development of MASH and fibrosis using a combination of clinical data from multiple independent patient cohorts, single-cell liver transcriptomics, and human in vitro and ex vivo models. Hepatic TLR5 expression, but not TLR2 or TLR4, is associated with liver fibrosis and mortality. Plasma levels of TLR5’s cognate ligand flagellin are increased in MASH with advanced fibrosis and fall with liver disease improvement. Mechanistically, we identify two parallel TLR5-mediated routes to hepatocyte injury: one elicited by flagellin and the other indirectly by lipid injury. Furthermore, hepatocyte TLR5 inhibition abrogates paracrine activation of hepatic stellate cells to suppress collagen production. This is also seen ex vivo in patient-derived precision-cut liver slices where TLR5 inhibition significantly reduces lipid-induced collagen deposition. These findings reveal a new role for TLR5 signaling, specifically in the development of advanced MASH fibrosis and may offer a novel disease-specific therapeutic approach.

Förderung

  • Eureka Therapeutics
  • Medical Research Council
  • Academy of Medical Sciences
  • Innovate UK
  • Guts UK
  • Medical College of Saint Bartholomews Hospital Trust
  • Bruker Spatial Biology, Research Foundation - Flanders
  • Barts Metabolism Network

Zitieren

APA

Li, W., Wang, N., Abyad, D. E., Anak, S., Kumar, R., Ginés, I., Gill, U., Hood, G., Brindley, J., Mein, C., Boot, J., Wilcox, U. R., Dufton, N., Goldin, R., Roskams, T., Loy, J., Devalia, K., Malik, H., Goralcyzk, A., …, & Alazawi, W. (2026). TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signaling. Science Advances, 12(47). https://doi.org/10.1126/sciadv.aef9541

Vancouver

Li W, Wang N, Abyad DE, Anak S, Kumar R, Ginés I, et al. TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signaling. Science Advances. 2026;12(47). doi:10.1126/sciadv.aef9541

BibTeX
@article{Li2026,
  author = {Li, Wenhao and Wang, Niannian and Abyad, Dania El and Anak, Seray and Kumar, Raju and Ginés, Iris and Gill, Upkar and Hood, Gillian and Brindley, James and Mein, Charles and Boot, James and Wilcox, Una Rose and Dufton, Neil and Goldin, Robert and Roskams, Tania and Loy, John and Devalia, Kalpana and Malik, Humza and Goralcyzk, Adam and Jimenez-Ramos, Maria and Kendall, Timothy J. and Fallowfield, Jonathan A. and Martins, Maria Ines Castanho and Rombouts, Krista and Vacca, Michele and Govaere, Olivier and Alazawi, William},
  title = {TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signaling},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {47},
  doi = {10.1126/sciadv.aef9541}
}
Kostenlos starten →